Recombinant Rat CD30/TNFRSF8 Fc Chimera Protein, CF

When Recombinant Mouse CD30 Ligand/TNFSF8 (732-CL) is immobilized at 0.250 μg/mL (100 μL/well), Recombinant Rat CD30/TNFRSF8 Mouse Fc Chimera Protein (Catalog # 11034-CD) binds with and ED50 of 20.0-120 ng/mL.

2 μg/lane of Recombinant Rat CD30/TNFRSF8 Mouse Fc Chimera Protein (Catalog # 11034-CD) was resolved with SDS-PAGE under reducing (R) and non-reducing (NR) conditions and visualized by Coomassie® Blue staining, showing bands at 80-95 kDa and 160-190 kDa, respectively.

• Reactivity: Rt
• Applications: Bioactivity
• Format: Carrier-Free

Recombinant Rat CD30/TNFRSF8 Fc Chimera Protein, CF Summary

• Details of Functionality: Measured by its binding ability in a functional ELISA. When Recombinant Mouse CD30 Ligand/TNFSF8 (Catalog # 732-CL/CF) is immobilized at 0.250 μg/mL (100 μL/well), Recombinant Rat CD30/TNFRSF8 Mouse Fc Chimera binds with and ED₅₀ of 20.0-120 ng/mL.
• Source: Mouse myeloma cell line, NS0-derived rat CD30/TNFRSF8 protein
  

  Rat CD30 (Phe19-Leu255) Accession # EDL81069.1	IEGRMDP	Mouse IgG2a (Glu98-Lys330)
  N-terminus		C-terminus

• Accession #: EDL81069.1
• N-terminal Sequence: Phe19
• Structure / Form: Disulfide linked homodimer
• Protein/Peptide Type: Recombinant Proteins
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Endotoxin Note: <0.10 EU per 1 μg of the protein by the LAL method.

Applications/Dilutions

• Dilutions:
  • Bioactivity
• Theoretical MW: 52 kDa.
  Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
• SDS-PAGE: 80-95 kDa, under reducing conditions.

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS.
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Reconstitution Instructions: Reconstitute at 500 μg/mL in PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Recombinant Rat CD30/TNFRSF8 Fc Chimera Protein, CF

• CD30 antigen
• CD30
• CD30KI-1
• CD30L receptor
• cytokine receptor CD30
• D1S166EKi-1
• Ki-1 antigen
• Lymphocyte activation antigen CD30
• TNFRSF8
• tumor necrosis factor receptor superfamily member 8
• tumor necrosis factor receptor superfamily, member 8

Background

Lymphocyte activation antigen CD-30 (CD30), also known as Tumor necrosis factor receptor superfamily member 8 (TNFRSF8), is a type I transmembrane glycoprotein belonging to the TNFR superfamily (1, 2). Mature rat CD30 consists of an extracellular domain (ECD) containing four disulfide bonds and two cysteine-rich repeats, a transmembrane domain, and a cytoplasmic domain. Within the ECD, rat CD30 shares 45% and 79% amino acid (aa) sequence identity with human and mouse CD30, respectively. In human, isoforms of CD30 with truncated cytoplasmic domains can be generated as well as a soluble form, which is produced by proteolytic cleavage of CD30 at the cell surface and is found in serum (3, 4). CD30 is normally expressed on antigen-stimulated Th cells and B cells (5 ‑ 7). CD30 binds to CD30 Ligand/TNFSF8 which is expressed on activated Th cells, monocytes, granulocytes and medullary thymic epithelial cells (2, 6). Signaling via CD30‑CD30L has been shown to induce the activation and proliferation of T cells and the CD30–CD30L pathway has been implicated as a major player in secondary humoral immune responses (2). In the absence of antigenic stimulation, CD30 can still induce T cell expression of IL‑13 (8). CD30 contributes to thymic negative selection by inducing the apoptotic cell death of CD4+CD8+ T cells (8, 9). In B cells, CD30 ligation promotes cellular proliferation and antibody production in addition to the expression of CXCR4, CCL3, and CCL5 (6, 10). Soluble CD30 retains the ability to bind CD30 Ligand and functions as an inhibitor of normal CD30 signaling (11). CD30 is up‑regulated in Hodgkin's disease (on Reed-Sternberg cells), other lymphomas, chronic inflammation, and autoimmunity (12).

1. Hehlgans, T. & Pfeffer, K. (2005) Immunology 115(1):1–20.
2. Kennedy, M.K. et al. (2006) Immunology 118:143.
3. van der Weyden, C.A. et al. (2017). Blood Cancer J. 7:e603
4. Buchan, S.L. and Al-Shamkhani, A. (2012) PLoS ONE 7:e45244.
5. Hamann, D. et al. (1996) J. Immunol. 156:1387.
6. Shanebeck, S.D. et al. (1995) Eur. J. Immunol. 25:2147.
7. Gruss, H.-J. et al. (1994) Blood 83:2045.
8. Harlin, H. et al. (2002) J. Immunol. 169:2451.
9. Amakawa, R. et al. (1996) Cell 84:551.
10. Vinante, F. et al. (2002) Blood 99:52.
11. Hargreaves, P.G. and A. Al-Shamkhani (2002) Eur. J. Immunol. 32:163.
12. Oflzoglu E. et al. (2009) Adv. Exp. Med. Biol. 647:174.

Bioinformatics

• Uniprot:
  • EDL81069.1()